Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiamin Cheng

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Hepatology (Baltimore, Md.)|June 18, 2016
SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cellsLimei Liu, Chungang Liu, Qianzhen Zhang, et al.
Frontiers in Oncology|November 28, 2022
Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patientsTao Yan, Chenyang Huang, Jin Lei, et al.
Annals of Translational Medicine|February 23, 2023
A multi-center retrospective study on the efficacy and safety of regorafenib <i>vs.</i> regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinomaTao Yan, Chenyang Huang, Caiyun Peng, et al.
Hepatology International|February 8, 2023
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patientsXu Yang, Bowen Chen, Yanyu Wang, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Hepatology (Baltimore, Md.)|June 18, 2016
SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cellsLimei Liu, Chungang Liu, Qianzhen Zhang, et al.
Frontiers in Oncology|November 28, 2022
Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patientsTao Yan, Chenyang Huang, Jin Lei, et al.
Annals of Translational Medicine|February 23, 2023
A multi-center retrospective study on the efficacy and safety of regorafenib <i>vs.</i> regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinomaTao Yan, Chenyang Huang, Caiyun Peng, et al.
Hepatology International|February 8, 2023
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patientsXu Yang, Bowen Chen, Yanyu Wang, et al.
Pageof 5